Cell MedX Corp
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
Cell MedX Corp (CMXC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2024: 0.017x
Based on the latest financial reports, Cell MedX Corp (CMXC) has a cash flow conversion efficiency ratio of 0.017x as of November 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.52K) by net assets ($-982.71K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cell MedX Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cell MedX Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cell MedX Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cell MedX Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
0.102x |
|
HOFFMANN GR.CEM.TEC. 1-
F:0VW
|
N/A |
|
BAJEL PROJECTS LTD
NSE:BAJEL
|
0.089x |
|
SKY LIGHT HOLDINGS LTD
F:27L
|
N/A |
|
TMT Steel Public Company Limited
BK:TMT
|
0.022x |
|
TAPEX INC
KO:055490
|
0.003x |
|
Q linea AB
ST:QLINEA
|
-0.118x |
|
LGL Group Inc
NYSE MKT:LGL
|
0.007x |
Annual Cash Flow Conversion Efficiency for Cell MedX Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cell MedX Corp from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-05-31 | $-826.46K | $-145.90K | 0.177x | +54.70% |
| 2023-05-31 | $-2.39 Million | $-272.21K | 0.114x | -15.78% |
| 2022-05-31 | $-2.01 Million | $-272.21K | 0.135x | -61.90% |
| 2021-05-31 | $-1.58 Million | $-560.43K | 0.356x | -41.61% |
| 2020-05-31 | $-1.52 Million | $-925.84K | 0.609x | +250.99% |
| 2019-05-31 | $-1.77 Million | $-307.54K | 0.174x | -58.56% |
| 2018-05-31 | $-1.07 Million | $-449.43K | 0.419x | -35.07% |
| 2017-05-31 | $-1.17 Million | $-754.06K | 0.645x | +116.07% |
| 2016-05-31 | $-1.41 Million | $-421.57K | 0.298x | -35.56% |
| 2015-05-31 | $-684.07K | $-316.81K | 0.463x | -3.40% |
| 2014-05-31 | $-20.39K | $-9.78K | 0.479x | -92.91% |
| 2013-05-31 | $-1.87K | $-12.64K | 6.764x | -- |